Geron

direction arrow
Pharma

Novartis refreshes myelofibrosis bid as Geron flops in ph. 3

Geron's Rytelo failed to move the needle in post-JAK myelofibrosis, as Novartis is gearing up for a delayed FDA approval bid for its pelabresib.
Angus Liu Oct 29, 2026 8:15am
layoffs downsizing job cuts staff cuts

Geron plots deep layoffs in bid to curb operating costs

Dec 11, 2025 1:50pm
Graphic of an open door with the words exit above it

Geron losing commercial chief shortly after first FDA approval

Jul 24, 2024 4:34am
Marathon

FDA signs off on Geron's long-awaited blood cancer drug Rytelo

Jun 7, 2024 12:03pm
Food and Drug Administration

Geron hires a host of commercial, marketing execs

Jan 13, 2023 9:15am